Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation
NCT ID: NCT00366613
Last Updated: 2018-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2005-07-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AquaLase Capsule Wash for Pediatric Eyes
NCT00756327
Clinical Trial : Complications of in the Bag IOL Versus Optic Capture of IOL in Pediatric Cataract Surgery
NCT02491918
Outcome of Capsular After Pediatric Cataract Surgery With Primary Intraocular Lens Implantation
NCT04357249
Optic Capture Without Anterior Vitrectomy in Pediatric Cataract Surgery
NCT05461040
Trying a New Device for Performing Capsulorhexis in Cataract Surgery Surgery
NCT01396967
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Removal of residual epithelial cells is one of the key factors to avoid the complication of PCO. Several chemicals have been suggested in experimental settings to remove or kill these residual lens epithelial cells. However, they are toxic to other ocular structures. Researchers are searching for a device which can help to selectively kill these lens epithelial cells. In the long term, this may help to avoid PCO.
Perfect Capsule: Perfect CapsuleTM (Milvella ltd) is a sterile single use ophthalmic instrument used to perform sealed irrigation of the capsular bag during cataract surgery in order to facilitate irrigation of the capsule without the irrigation fluid contacting other ocular structures. The device has the FDA approval via 510(k) in the USA, and is CE marked in Europe. No specific age limit has been listed for FDA approval. The device (see fig) consists of a 7 mm diameter head, a 3 mm wide body and a 4 mm wide foot that remains external to the eye. The head of the device comprises a circumferential vacuum channel connected to a vacuum syringe via a vacuum tube. The central portion of the head forms a plug with an irrigation/aspiration (I/A) channel (the body) which extend through the cornea allowing fluids to be injected into the under surface of the plug and thus into the capsule. The device has an internal diameter of 5 mm, is molded in medical grade silicone, packaged and gamma sterilized. It can be easily rolled or folded to pass through the standard corneal incision into the eye and positioned on the anterior surface of the capsule using standard ophthalmic instrument.
Concentrated Sodium Chloride: Concentrated Sodium Chloride injection, USP 23.4% (American Regent Laboratories, Inc., Shirley, NY) is sterile, preservative free, nonpyrogenic solution of Sodium Chloride in water for injection. Deionised water has been shown to lyse lens epithelial cells through osmotic flow. Concentrated Sodium Chloride is not currently indicated for intraocular use and is also expected to affect the corneal endothelium. Use of Perfect Capsule will help to avoid the contact of Concentrated sodium Chloride to the endothelial cells.
For the purpose of this study, Concentrated Sodium Chloride for injection will be colored with minimal fluorescein so that the flow and location of it can be visualized throughout the procedure. Viscoelastic within the anterior chamber will provide additional protection for the corneal endothelium.
SCI with Perfect Capsule and Concentrated Sodium Chloride: Perfect CapsuleTM allows for the empty capsular bag to be irrigated with Concentrated Sodium Chloride. A previous study in rabbits has shown that toxic solutions can be safely used for SCI. It has also been shown that the irrigation solution is contained within the capsular bag when SCI is performed in humans. Dr. Auffarth has presented a summary of the two year Australian study results and one year European multi-center clinical trial results performing SCI with distilled water in humans (At American Society of Cataract and Refractive Surgery meeting, 2005). In 44 patients studied, the system could be used without complication and the endothelial cell count and corneal pachymetry was not different from the control eyes. Visual acuity development over a 6-12 months period was similar in both groups. Retro-illumination photographs showed a higher incidence of fibrosis and anterior capsule whitening in the control group compared to the SCI group. With the currently available IOLs, PCO is not a significant complication in adult eyes at 1-2 year postoperative period. Long-term results will be needed to detect the difference (if any) in terms of PCO in adult eyes. In contrast, PCO is a significant problem in pediatric eyes. It occurs at a much faster rate and during early postoperative period in children's eyes as compared to adult's eyes. Younger the child at the time of cataract surgery, more acute is the problem. Thus, it is possible to see the difference in terms of PCO (if any) with the use of Perfect Capsule in children's eyes during early postoperative period, as 1 year postoperatively in this study. We are not aware of any published results or results presented at the meeting showing use of SCI or distilled water in pediatric eyes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cataract surgery with Perfect Capsule and Sodium Chloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 4 - 18 years of age
* Informed consent from the parents/legal guardian.
Exclusion Criteria
* fellow eye - visually not significant cataract
* fellow eye surgery not planned during the study enrollment period
* weak or compromised posterior or anterior capsule
* dense posterior capsule plaque
* preexisting posterior capsule defect
* capsulorhexis diameter\>5 mm
* radial capsular tears
* defects within the remaining capsular bag
* inability to visualize the entire capsulorhexis
* shallow anterior chamber
* very high vitreous pressure
4 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of South Carolina
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marion E Wilson, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of South Carolina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Storm Eye Institute, Medical University of South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SEI-06-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.